Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
myfortic magasýruþolin tafla 180 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
myfortic magasýruþolin tafla 360 mg
novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tobradex augndropar, dreifa
novartis healthcare a/s - dexamethasonum fosfat; tobramycinum inn - augndropar, dreifa
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
kesimpta
novartis ireland ltd - ofatumumab - heila-og mænusigg, köstum tilkynnt - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
sandimmun innrennslisþykkni, lausn 50 mg/ml
novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
diovan mixtúra, lausn 3 mg/ml
novartis healthcare a/s - valsartanum inn - mixtúra, lausn - 3 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
certican tafla 0,75 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
certican tafla 0,5 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
trileptal mixtúra, dreifa 60 mg/ml
novartis healthcare a/s - oxcarbazepinum inn - mixtúra, dreifa - 60 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
certican tafla 0,25 mg
novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg